No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 127,853 | 137,760 | 152,135 | 169,567 | 186,443 | 195,247 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | -27,753 | -6,804 | 7,868 | -4,525 | -3,035 | 1,895 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
MYUNGMOON Pharm Co., Ltd. operates as a pharmaceutical enterprise, comprehensively handling the research, development, production, distribution, and commercialization of medicinal products. Its business activities extend across South Korea and into global markets. The company offers an extensive array of prescription drugs, addressing a broad spectrum of medical conditions. This range includes treatments for musculoskeletal issues like osteoarthritis, inflammation, rheumatoid arthritis, and muscle relaxation, alongside anti-infectives (antibiotics and antifungals), respiratory aids, and gastrointestinal therapeutics. Cardiovascular health is targeted with circulation agents, anti-hypertensive drugs, and antidiabetic medications. Furthermore, their specialized pharmacotherapy solutions cover narcotics, anesthetics, central nervous system agents, female hormone products, osteoporosis treatments, urogenital medications, adrenocortical hormones, oncology drugs, dermal fillers, and anti-obesity agents. Beyond prescription items, MYUNGMOON Pharm also supplies a diverse selection of over-the-counter (OTC) remedies. These encompass medications for nausea, genitourinary concerns, gum disease, liver support, parasitic infections, constipation, oral ailments, diarrhea, and general digestive health. The OTC portfolio further includes cold and flu treatments, calcium supplements, nasal sprays, multi-vitamins, eye nutrition products, eye drops, blood circulation enhancers, and topical preparations such as external skin treatments and localized pain relievers. In addition to its pharmaceutical lines, the firm markets health supplements, quasi-pharmaceuticals, and blended juice beverages. Established in 1983, MYUNGMOON Pharm Co., Ltd. maintains its primary corporate office in Seoul, South Korea.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
MYUNGMOON Pharm co.,Ltd (017180.KS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
MYUNGMOON Pharm Co., Ltd. operates as a pharmaceutical enterprise, comprehensively handling the research, development, production, distribution, and commercialization of medicinal products. Its business activities extend across South Korea and into global markets. The company offers an extensive array of prescription drugs, addressing a broad spectrum of medical conditions. This range includes treatments for musculoskeletal issues like osteoarthritis, inflammation, rheumatoid arthritis, and muscle relaxation, alongside anti-infectives (antibiotics and antifungals), respiratory aids, and gastrointestinal therapeutics. Cardiovascular health is targeted with circulation agents, anti-hypertensive drugs, and antidiabetic medications. Furthermore, their specialized pharmacotherapy solutions cover narcotics, anesthetics, central nervous system agents, female hormone products, osteoporosis treatments, urogenital medications, adrenocortical hormones, oncology drugs, dermal fillers, and anti-obesity agents. Beyond prescription items, MYUNGMOON Pharm also supplies a diverse selection of over-the-counter (OTC) remedies. These encompass medications for nausea, genitourinary concerns, gum disease, liver support, parasitic infections, constipation, oral ailments, diarrhea, and general digestive health. The OTC portfolio further includes cold and flu treatments, calcium supplements, nasal sprays, multi-vitamins, eye nutrition products, eye drops, blood circulation enhancers, and topical preparations such as external skin treatments and localized pain relievers. In addition to its pharmaceutical lines, the firm markets health supplements, quasi-pharmaceuticals, and blended juice beverages. Established in 1983, MYUNGMOON Pharm Co., Ltd. maintains its primary corporate office in Seoul, South Korea.